Two New Antibiotics Treat Severe Skin Infections
Diane S. Aschenbrenner
Abstract
Diane S. Aschenbrenner
Abstract
Two new antibiotics, tedizolid (Sivextro) and oritavancin (Orbactiv), were recently approved to treat serious skin and skin-structure infections. Tedizolid is given for six days either orally or intravenously. The most common adverse effects are nausea, headache, diarrhea, vomiting, and dizziness. Oritavancin is given as a single IV dose. The most common adverse effects are headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Two new antibiotics, tedizolid (Sivextro) and oritavancin (Orbactiv), were recently approved to treat serious skin and skin-structure infections. Tedizolid is given for six days either orally or intravenously. The most common adverse effects are nausea, headache, diarrhea, vomiting, and dizziness. Oritavancin is given as a single IV dose. The most common adverse effects are headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea.
Key concepts: Vomiting, Nausea, Medicine, Diarrhea, Adverse effect, Antibiotics, Skin infection, Anesthesia